tbuckley/cabot-search huggingface dataset:
PTU-059 Which correlation among histological assessment of fibrosis, non-invasive markers and portal hypertension in HCV transplanted patients?
Authors: G Isgro, V Calvaruso, P Manousou, T Luong, L Andreana, S Maimone, L Makalanda, L Marelli, D Patch, N Davies, J O'Beirne, A Dhillon, A Burroughs
Journal: Gut (2010)

<h3>Introduction</h3> HVPG is an established marker of portal hypertension, while transient elastography (TE) has been proposed as a non-invasive marker of portal hypertension/disease progression. Collagen proportionate area (CPA),1 a histological quantitation of liver collagen, was recently shown to be a better correlate with HVPG than Ishak stage. The aim of this study is to evaluate relationships between liver collagen, TE, APRI score, HVPG and Ishak stage. <h3>Methods</h3> Consecutive HCV transplanted patients had transjugular liver biopsies combined with HVPG, TE and CPA. Linear regression analysis was used to assess correlation: CPA and TE, and CPA, TE and HVPG. ROC curves to assess sensitivities/specificities of each factor. <h3>Results</h3> 58 HCV transplanted patients: 47 males, mean age 53 years, mean time 50±39 (9–169) months from LT. Median liver stiffness (LSM) 11.3 kPa (3.1–50.3), mean HVPG 5 mm Hg (0–32), mean CPA 7.9% (1–45), mean APRI score 0.06 (0.01–0.7). Correlation between LSM and CPA r<sup>2</sup>=0.58, (p&lt;0.000), between LSM and HVPG r<sup>2</sup>=0.16; (p=0.002) and CPA and HVPG r<sup>2</sup>=0.28(p&lt;0.000). Univariately CPA, Ishak stage, TE (all p&lt;0.0001), APRI score (p=0.04) were associated with HVPG≥6 mm Hg; multivariately CPA was the only independent factor (OR 1.336, 95% CI 1.136 to 1.571, p=0.000). Univariately CPA, Ishak stage, TE and APRI score were also associated with HVPG≥10 mm Hg but multivariately only CPA (OR 1.1, 95% CI 1.02 to 1.2, p=0.020). For HVPG≥6 mm Hg, AUROC for CPA was 0.91(95% CI 0.83 to 0.99). The best cut-off was 8.7% (78% sensitivity and 87% specificity); AUROC for stiffness was 0.83 (95% CI 0.70 to 0.96), cut-off of 10.9 kPa had 78% sensitivity and 87% specificity. For CPA &gt;8%, the AUROC for stiffness was 0.98(95% CI 0.96 to 1.011). A cut-off of 9.6 kpa could predict CPA&gt;8% (93% sensitivity and 99% specificity). For stiffness&gt;11 kPa, AUROC for CPA was 0.96(95% CI 0.89 to 1.018) with a cut-off of 8.4% (87% sensitivity and 99% specificity). <h3>Conclusion</h3> CPA as a quantitative measure of liver collagen had a better correlation with TE than HVPG. Thus it may represent a better histological index for TE rather than stages which are descriptive categories and not quantitative assessments. CPA was better than Ishak stage or TE in predicting portal hypertension. CPA should be evaluated to subclassify cirrhosis.
THE RELATION OF THE MEDICAL EXAMINER TO THE MEDICAL DIRECTOR.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction of 95% CI in Table
Authors: Alexios Antonopoulos, Gerasimos Siasos, Dimitris Tousoulis, Benjamin Scirica
Journal: JAMA Cardiology (2017)

Husam Abdel-Qadir, MD; Peter C. Austin, PhD; Douglas S. Lee, MD, PhD; Eitan Amir, MB, ChB, PhD; Jack V. Tu, MD, PhD; Paaladinesh Thavendiranathan, MD, MSc; Kinwah Fung, MSc; Geoffrey M. Anderson, MD, PhD
The Need for More Physicians
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary Edema Due to Tetrachloroethylene
Authors: Ramesh Patel, Natesan Janakiraman, William D. Towne
Journal: Environmental Health Perspectives (1977)

A patient with massive exposure to tetrachloroethylene fumes presented with coma and severe pulmonary edema. Sequential blood gases, chest x-rays, and clinical findings showed dramatic improvement with conventional but aggressive management and the patient recovered completely. There was no evidence of permanent renal, hepatic, or central nervous system damage.
Highlights
Journal: JAMA (2019)

Corticosteroid-Sparing Treatments for Noninfectious Uveitis 936Some evidence suggests that mycophenolate mofetil may be superior to methotrexate for initial treatment of noninfectious uveitis.Rathinam and colleagues randomized 216 adults with noninfectious uveitis and found that the use of mycophenolate mofetil, compared with methotrexate, as fi rst-line corticosteroid-sparing treatment did not result in superior control of infl ammation.Visual Abstract jama.comCME jamanetwork.com/learning Home-Based Physical Training After Hip Fracture 946The benefi t of exercise interventions for patients with hip fracture may be attributable to the treatment itself or to the experience of receiving intensive contact with well-trained professionals.Magaziner and colleagues randomized 210 older adults with hip fracture and found that a multicomponent home-based physical therapy intervention, compared with an active control that included transcutaneous electrical nerve stimulation and active range-of-motion exercises, did not result in a statistically signifi cant improvement in the ability to walk 300 m or more in 6 minutes after 16 weeks.
Infantile Mortality and Infants' Milk Depot.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE USE OF ANTISERUMS IN THE TREATMENT OF DISEASE
Authors: FREDERICK P. GAY
Journal: JAMA (1923)

Thirty-five years have elapsed since Hericourt and Richet demonstrated the fact that the serum of dogs that had been actively immunized against a certain staphylococcus had, by transfusion, the property of curing otherwise fatal infections due to this organism in unprepared rabbits. This important principle of transferred or passive immunity has since that time been repeatedly demonstrated experimentally in connection with many other pathogenic bacteria and their toxins. It is fortunate that the first complete study of passive immunity by Behring and Kitasato was with the soluble toxins of the tetanus and the diphtheria bacillus, so that the results, not only experimentally in animals but also in the treatment of human disease, were so unequivocal that the study of the principles and practice of serum therapy has never since languished. And yet in the intervening thirty-three years, no other such striking instances of serum therapy have been encountered, no other
Lessons in the Anatomy, Physiology and Hygiene of Infancy and Childhood, for Junior Students.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mad Cow Disease
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ON BORROWED TIME
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Section Registration
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
25511 Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
Authors: Eric L. Simpson, Marjolein S. de Bruin-Weller, Vimal H. Prajapati, Brian M. Calimlim, Henrique D. Teixeira, Jiewei Zeng, Meng Liu, Jonathan I. Silverberg
Journal: Journal of the American Academy of Dermatology (2021)
Married.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells
Authors: K.-L. Ellis, R. Mohammad, S. Wang, X. Wu, J. Chen, J. Min, F. H. Sarkar
Journal: Journal of Clinical Oncology (2004)

3133 Background: Several important survival molecules such as NF-κB and Bcl-XL are highly activated in pancreas cancer. NF-κB is responsible for transcriptional activation of many tumor-promoting genes including Bcl-XL. We have previously shown that genistein down regulates the activation of NF-κB, and in turn decreases Bcl-XL. We have also shown that a small molecule inhibitor (SMI) BL-193 is a potent inhibitor of Bcl-XL,and to a lesser degree of Bcl-2. Therefore, we hypothesize that inactivation of NF-κB by genistein leads to decreased transcription of Bcl-XL,which will lead to the induction of apoptotic cell death. We also hypothesize that complete inactivation of Bcl-XLmay not be achievable by genistein treatment alone, therefore further inactivation of residual Bcl-XLby BL-193 may lead to complete inactivation of Bcl-XL, thereby enhancing the killing of pancreatic cancer cells. Methods: Results: In support of our hypotheses, we have shown by MTT assay that 30 μM genistein exposure of BxPC-3 pancreatic cancer cells for 24 hours caused inhibition in cell growth. We have also demonstrated that treatment with 3μM BL-193 alone for 72 hours caused significant growth inhibition. Moreover, cells pre-treated for 24 hours with genistein followed by 72 hours of BL-193 demonstrated significantly greater growth inhibition compared to either agent alone. The observed growth inhibition could be due to either cell cycle arrest or induction of apoptosis hence we determined the degree of apoptosis induced by these agents alone or in combination as analyzed by Histone-DNA ELISA. We found that BL-193-induced apoptosis was much more pronounced in cells pre-treated with genistein, and the results were correlated with genistein-induced inactivation of NF-κB and Bcl-XL. Conclusions: These results are consistent with our hypotheses and suggest that pre-treatment of pancreatic cancer cells with genistein down regulates NF-κB and Bcl-XL, which may play important roles in potentiating the apoptosis-inducing effect of BL-193. No significant financial relationships to disclose.
Computed tomography in the early detection of skeletal involvement with multiple myeloma
Authors: C. A. Helms
Journal: JAMA (1982)

IT IS generally accepted that approximately 25% to 50% of the trabecular spongiosum in the vertebrae must be resorbed or destroyed to be detected by conventional roentgenography.<sup>1</sup>Radionuclide bone scanning is more sensitive in detecting focal osseous destruction based on the dynamic state of reactive osteoblastic activity and/or increased regional bone blood flow. Specifically, however, in multiple myeloma, bone scans are frequently falsely negative, and conventional roentgenography continues to be the principal imaging modality to assess skeletal involvement.<sup>2-4</sup>This case illustrates a potentially sensitive method of detecting early skeletal destruction in multiple myeloma using high-resolution computed tomography (CT). <h3>Report of a Case</h3> A 43-year-old woman with known multiple myeloma had low-back pain and sciatica. Conventional roentgenograms of the lumbosacral spine demonstrated mild generalized demineralization but no focal abnormalities (Fig 1); CT of the lumbar spine was performed to evaluate lumbar disk disease. Serial scans disclosed a protruding disk
Hepatitis
Authors: Frank L. Iber
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2336: Clinical-pathological characterization of the immunomodulator subgroup of triple negative breast cancer as a promising step in the selection of patients in personalized immunotherapies
Authors: Ruben R. Bautista, Oscar Gerardo A. Rodríguez, Alfredo H. Miranda, Alejandro Z. Dehesa
Journal: Cancer Research (2019)

Abstract Introduction: Triple Negative Breast Cancer (CMTN) represents 23.1% of breast cancer cases in Mexico, is defined as a tumor that is absent of hormone receptors (estrogen and progesterone) and low HER2 overexpression and clinically is characterized by its agressive tumoral behavior. Lehmann et al. described an immunomodulatory (IM) group which is composed of genes for immune antigens and transduction pathways of immune signals and cytokines. Recent studies have shown that patients with the IM phenotype have a better prognosis. So it is important to continue with the description of this subgroup as the first step for personalized therapies in this heterogeneous tumor. Methodology: Retrospective clinical study, patients with diagnosis of CMTN, attended at the National Cancer Institute of Mexico (Total: 69 patients) were included. Following, the extraction of RNA from the primary tumor tissue of CMTN paraffin blocks was performed to subsequently generate labeled cDNA for hybridization in Affymetrix® Human Gene 2.0 microarrays, to later carry out the scanning and analysis of the data. For the analysis of microarrays we used the free software R and Bioconductor.65. And then the classification of patients using the platform "TNBCtype (http://cbc.mc.vanderbilt.edu/tnbc/)". And finally the analysis of survival, univariate and multivariate through SPSS. Results: We observed some clinical variables with statistical difference such as radiotherapy (p&amp;lt;0.001), metastasis to lung (p=0.009), liver (p=0.013), and central nervous system (p=0.0029), as well as the Lehmann classifier showed significant difference between patients classified as IM vs. No IM (p=0.04). Conclusions: the IM classifier could not only serve as an excellent prognostic classification in CMTN but as a predictor of immunological treatments. Citation Format: Ruben R. Bautista, Oscar Gerardo A. Rodríguez, Alfredo H. Miranda, Alejandro Z. Dehesa. Clinical-pathological characterization of the immunomodulator subgroup of triple negative breast cancer as a promising step in the selection of patients in personalized immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2336.